Literature DB >> 8527291

Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.

W Cawello1, A Leonhardt, H Schweer, H W Seyberth, R Bonn, A L Lomeli.   

Abstract

Prostaglandin E1 (PGE1) (30, 60, 120 micrograms) was administered by intravenous infusion over a 120 min period in an open, three way randomized, cross-over study to 12 healthy male volunteers. For the evaluation of PGE1, PGE0 and 15-keto-PGE0, blood samples were drawn prior to, during and after the infusion. Analytical measurements were performed by gas chromatography/negative ion chemical ionization triple stage quadruple mass spectrometry, a highly specific and sensitive GC/MS/MS-method. During intravenous infusion of 30, 60 and 120 micrograms PGE1, endogenous plasma PGE1 concentrations increased from 1.7 +/- 0.8 to 4.2 +/- 1.1, 6.7 +/- 1.0 and 11.0 +/- 1.9 pg ml-1 respectively. PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively. Within the dose range of 30-120 micrograms PGE1 2 h-1 there was a linear increase of Cmax and AUC with the dose. The results of the analysis of variance after baseline and dose-correction show a 90% confidence interval in the bioequivalence acceptance range of 80 to 125%.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527291      PMCID: PMC1365109          DOI: 10.1111/j.1365-2125.1995.tb05784.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Clinical, hemodynamic and metabolic effects of intraarterial infusions of prostaglandin E1 in patients with peripheral vascular disease.

Authors:  A G Olsson; L A Carlson
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1976

2.  Utilization of cyclodextrin complexation for separation of E, A, and B prostaglandins by ion-exchange liquid chromatography.

Authors:  K Uekama; F Hirayama; K Ikeda; K Inaba
Journal:  J Pharm Sci       Date:  1977-05       Impact factor: 3.534

3.  Endogenous levels of 15-keto-dihydro-prostaglandins in human plasma. Parameters for monitoring prostaglandin synthesis.

Authors:  B Samuelsson; K Gréen
Journal:  Biochem Med       Date:  1974-11

4.  On the metabolism of prostaglandins E 1 and E 2 in man.

Authors:  M Hamberg; B Samuelsson
Journal:  J Biol Chem       Date:  1971-11-25       Impact factor: 5.157

5.  Simulation of pharmacokinetic behaviour of drug-cyclodextrin complexes.

Authors:  I Habon; S Fritsch; J Szejtli
Journal:  Pharmazie       Date:  1984-12       Impact factor: 1.267

6.  Relationship between chemical structure and platelet-aggregation activity of prostaglandins.

Authors:  J Kloeze
Journal:  Biochim Biophys Acta       Date:  1969-10-28

7.  On the metabolism of prostaglandin E1 administered intravenously to human volunteers.

Authors:  B A Peskar; W Cawello; W Rogatti; G Rudofsky
Journal:  J Physiol Pharmacol       Date:  1991-09       Impact factor: 3.011

8.  Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease.

Authors:  M Hirai; R Nakayama
Journal:  Br J Surg       Date:  1986-01       Impact factor: 6.939

9.  Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.

Authors:  G Trübestein; S von Bary; K Breddin; C Diehm; J D Gruss; H Heinrich; S Horsch; A Kriessmann; U Maass; M Martin
Journal:  Vasa Suppl       Date:  1989

10.  Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.

Authors:  W Cawello; H Schweer; R Müller; R Bonn; H W Seyberth
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more
  7 in total

1.  Confidence interval criteria for assessment of dose proportionality.

Authors:  B P Smith; F R Vandenhende; K A DeSante; N A Farid; P A Welch; J T Callaghan; S T Forgue
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

2.  Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis.

Authors:  A Fabbri; D Magalotti; M Brizi; G Bianchi; M Zoli; G Marchesini
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

3.  Effect of prostaglandin E1 inhalation on pulmonary hypertension following corrective surgery for congenital heart disease.

Authors:  Chun-Yan Zhang; Zeng-Shan Ma; Long-Le Ma; Le-Xin Wang
Journal:  Exp Clin Cardiol       Date:  2013

4.  Expression of the oxygen-sensitive transcription factor subunit HIF-1α in patients suffering from secondary Raynaud syndrome.

Authors:  Lukas Andreas Heger; Mark Kerber; Marcus Hortmann; Samuel Robinson; Maximilian Mauler; Daniela Stallmann; Daniel Duerschmied; Christoph Bode; Christoph Hehrlein; Ingo Ahrens
Journal:  Acta Pharmacol Sin       Date:  2018-07-10       Impact factor: 6.150

5.  Ischemic preconditioning vs adenosine vs prostaglandin E1 for protection against liver ischemia/reperfusion injury.

Authors:  M Radojkovic; M Stojanovic; G Stanojevic; D Radojkovic; J Gligorijevic; I Ilic; N Stojanovic
Journal:  Braz J Med Biol Res       Date:  2017-07-20       Impact factor: 2.590

6.  Antiplatelet agents can promote two-peaked thrombin generation in platelet rich plasma: mechanism and possible applications.

Authors:  Ivan D Tarandovskiy; Elena O Artemenko; Mikhail A Panteleev; Elena I Sinauridze; Fazoil I Ataullakhanov
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

7.  Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions.

Authors:  Kengo Suzuki; Kenichiro Nishi; Satoshi Takabuchi; Shinichi Kai; Tomonori Matsuyama; Shin Kurosawa; Takehiko Adachi; Takayuki Maruyama; Kazuhiko Fukuda; Kiichi Hirota
Journal:  PeerJ       Date:  2013-11-28       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.